NCT05283980View on ClinicalTrials.gov

Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Pain, PostoperativePain, AcutePain, ChestPainSatisfaction, PatientOpioid Use, UnspecifiedOpioids; Harmful Use
Interventions
DRUG

0.25% Bupivacaine

The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline

Trial Locations (1)

02130

BIDMC, Boston

All Listed Sponsors
lead

Beth Israel Deaconess Medical Center

OTHER